Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3262-3268

  Den Boer, M L ^a   Harms, D O ^a   Pieters, R ^a   Kazemier, K M ^a   Gobel U ^a   Korholz D ^a   Graubner, U ^a   Haas, R J ^a   Jorch, N ^a   Spaar, H J ^a   Kaspers, G J L ^a   Kamps, W A ^a   Van Der Does Van Den Berg, A ^a   Van Wering, E R ^a   Veerman, A J P ^a   Janka Schaub, G E ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ACUTE LYMPHOCYTIC LEUKEMIA; CHI SQUARE DISTRIBUTION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; INFANT; MALE; NONPARAMETRIC TEST; PATIENT SELECTION; PREDICTION AND FORECASTING; PRESCHOOL CHILD; RISK; STANDARD;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; RISK; STATISTICS, NONPARAMETRIC; VINCRISTINE;

EID: 0141799965     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.031     Document Type: Article

References (38)

1. Conter V, Arico M, Valsecchi MG, et al: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 14:2196-2204, 2000
2. Schrappe M, Reiter A, Zimmermann M, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 14:2205-2222, 2000
3. Gaynon PS, Trigg ME, Heerema NA, et al: Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14:2223-2233, 2000
4. Harms DO, Janka-Schaub GE: Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89, and 92. Leukemia 14:2234-2239, 2000
5. Kamps WA, Bökkerink JPM, Hählen K, et al: Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 94:1226-1236, 1999
6. Silverman LB, Declerck L, Gelber RD, et al: Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 14:2247-2256, 2000
7. Pui CH, Boyett JM, Rivera GK, et al: Long-term results of Total Therapies studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 14:2286-2294, 2000
8. Maloney KW, Shuster JJ, Murphy S, et al: Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 14:2276-2285, 2000
9. Henze G, Fengler R, Hartmann R, et al: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): A relapse study of the BFM group. Blood 78:1166-1172, 1991
10. Lawson SE, Harrison G, Richards S, et al: The UK experience in treating relapsed childhood acute lymphoblastic leukemia: A report on the medical research council UKALLR1 study. Br J Haematol 108:531-543, 2000
11. Pieters R, Kaspers GJL, Van Wering ER, et al: Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 7:392-397, 1993
12. Ramakers-van Woerden NL, Pieters R, Hoelzer D, et al: In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: A report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 38:379-386, 2002
13. Klumper E, Pieters R, Veerman AJP, et al: In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86:3861-3868, 1995
14. Hongo T, Fujii Y: Childhood leukemic cells and the clinical value of assay directed chemotherapy, in Kaspers GJL, Pieters R, Twentyman PR, et al (eds): Drug Resistance in Leukemia and Lymphoma. Chur, Switzerland, Harwood Academic Publishers, 1993, pp 313-319
15. Zwaan CM, Kaspers GJL, Pieters R, et al: Cellular drug resistance profiles in childhood acute myeloid leukemia: Differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96:2879-2886, 2000
16. Kaspers GJL, Veerman AJP, Pieters R, et al: In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90:2723-2729, 1997
17. Hongo T, Yajima S, Sakurai M, et al: In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89:2959-2965, 1997
18. Kaspers GJL, Veerman AJP, Pieters R, et al: Mononuclear cells contaminating leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 70:1047-1052, 1994
19. Kaspers GJL, Pieters R, Van Zantwijk CH, et al: In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64:469-474, 1991
20. Pieters R, Huismans DR, Loonen AH, et al: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338:399-403, 1991
21. Kamps WA, Bökkerink JPM, Hakvoort-Cammel FGAJ, et al: BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of the DCLSG protocol ALL-8 (1991-1996). Leukemia 16:1099-1111, 2002
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35:1-39, 1977
24. Kaspers GJL, Pieters R, Van Zantwijk CH, et al: Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 19:407-416, 1995
25. Kaspers GJL, Smets LA, Pieters R, et al: Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study. Blood 85:751-756, 1995
26. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al: TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 96:1094-1099, 2000
27. Hubeek I, Ramakers-van Woerden NL, Pieters R, et al: TEL/AML1 fusion is not a prognostic factor in Dutch childhood acute lymphoblastic leukaemia. Br J Haematol 113:254-255, 2001
28. Preisler HD, Gopal V: Regrowth resistance in leukemia and lymphoma: The need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res 18:149-160, 1994
29. Szczepanski T, Orfao A, van der Velden VH, et al: Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417, 2001
30. Borgmann A, Hartmann R, Schmid H, et al: Isolated extramedullary relapse in children with acute lymphoblastic leukemia: A comparison between treatment results of chemotherapy and bone marrow transplantation. Bone Marrow Transplant 15:515-521, 1995
31. Sadowitz PD, Smith SD, Shuster J, et al: Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 81:602-609, 1993
32. Yeoh EJ, Ross ME, Shurtleff SA, et al: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143, 2002
33. Veerman AJP, Hählen K, Kamps WA, et al: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-918, 1996
34. Nachman J, Sather HN, Gaynon PS, et al: Augmented Berlin-Frankfurt- Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the Children's Cancer Group. J Clin Oncol 15:2222-2230, 1997
35. Hwang WS, Chen LM, Huang SH, et al: Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test. Leuk Res 17:685-688, 1993
36. Pieters R, Huismans DR, Leyva A, et al: Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 59:217-220, 1989
37. Kirkpatrick DL, Duke M, Goh TS: Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk Res 14:459-466, 1990
38. Twentyman PR, Fox NE, Rees JKH: Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br J Haematol 71:19-24, 1989